- |||||||||| Clinical, Retrospective data: The prevalence of sarcopenia in patients with chronic pancreatitis: a meta-analysis (Pubmed Central) - Mar 23, 2021
The present meta-analysis demonstrated that sarcopenia is a common complication of CP and is observed in about 2 out of 5 patients with this inflammatory disease of the pancreas. Given the high incidence of adverse outcomes associated with sarcopenia, it is necessary to promptly diagnose this pathological condition in patients with CP.
- |||||||||| Journal: Role of Ultrasonography in Estimating Muscle Mass in Sarcopenic Obesity. (Pubmed Central) - Mar 20, 2021
This, in combination with the high incidence of both malnutrition and sarcopenia, warrants individual nutrition assessment in MD patients. US evaluation of muscle mass may be more accurate than BIA-derived skeletal muscle index assessment for the diagnosis of SO.
- |||||||||| Review, Journal, HEOR: Physical Function, Physical Activity and Quality of Life After Liver Transplantation: A Review. (Pubmed Central) - Mar 19, 2021
Developing evidence-based standards for post-liver transplant physical activity baseline testing and sustainment of intensity and quality is a key unmet need in transplant hepatology. At present it is reasonable for transplant teams to assess fitness and design a tailored exercise program when a recipient is first discharged, to record and reinforce progress at all post-transplant visits, and to set realistic long term performance goals that will often achieve recommended standards for the healthy general population.
- |||||||||| Clinical, Journal: Use of Skeletal Muscle Index as a Predictor of Wait List Mortality in Patients with End-Stage Liver Disease. (Pubmed Central) - Mar 19, 2021
Utilizing the pre-specified definitions of sarcopenia based on SMI, there was no statistically significant difference in mortality and delisting from the transplant wait list between patients with and without sarcopenia in this population. Practice and region-specific patterns for pre-transplant selection and median MELD at transplant may affect SMI as a predictor of waitlist mortality.
- |||||||||| Biomarker, Review, Journal: Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps. (Pubmed Central) - Mar 19, 2021
Our conclusion is that although myostatin alone might not prove to be a feasible biomarker, it could become an important part of a recently proposed panel of muscle wasting biomarkers. However, a thorough understanding of the interrelationship of these markers, as well as establishing a valid measurement methodology for myostatin and revising current research data in the light of new criteria of sarcopenia, is needed.
- |||||||||| Journal: Defining an international cut-off of two-legged countermovement jump power for sarcopenia and dysmobility syndrome. (Pubmed Central) - Mar 19, 2021
However, a thorough understanding of the interrelationship of these markers, as well as establishing a valid measurement methodology for myostatin and revising current research data in the light of new criteria of sarcopenia, is needed. Sex-specific jump power cut-offs were found to detect the presence of either sarcopenia or dysmobility syndrome in older adults independent of Asian or Caucasian ethnicity.
- |||||||||| Clinical, Journal: Vitamin D Deficiency and Sarcopenia in Hip Fracture Patients. (Pubmed Central) - Mar 19, 2021
Vitamin D deficiency was more prevalent in patients undergoing HFS than in patients undergoing elective THA. Among patients undergoing HFS, vitamin D deficiency was more prevalent in sarcopenic than in non-sarcopenic patients.
- |||||||||| NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Muscle Insulin Resistance in Aging (Mirage) (clinicaltrials.gov) - Mar 18, 2021 P=N/A, N=200, Active, not recruiting, Due to this unique feature of satellite cells, hyperglycemia may negatively affect the regenerative capability of skeletal muscle myofibers and thus facilitate sarcopenia. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Journal: Molecular changes associated with spinal cord aging. (Pubmed Central) - Mar 18, 2021
Furthermore, blood-spinal cord barrier (BSCB) permeability is increased in old mice, which may contribute to alterations in spinal cord homeostasis and exacerbate neuronal distress. Together, these data show for the first time that the spinal cord undergoes significant changes during aging, including progressive α-MNs loss that is associated with low-grade inflammation, apoptosis, changes in ECM, myelination, and vascular permeability.
- |||||||||| Review, Journal: Interactions between Muscle and Bone-Where Physics Meets Biology. (Pubmed Central) - Mar 18, 2021
Lessons from unloading, microgravity, and disuse teach us that gratuitous tissue is removed or reorganized while immobility and inflammation trigger muscle and bone marrow fatty infiltration and propagate degenerative diseases such as sarcopenia and osteoporosis. Ongoing research will certainly find new therapeutic targets for prevention and treatment.
- |||||||||| Review, Journal: The Potential Role of Fish-Derived Protein Hydrolysates on Metabolic Health, Skeletal Muscle Mass and Function in Ageing. (Pubmed Central) - Mar 18, 2021
In particular, the effects of acute and chronic FPH consumption on post-exercise aminoacidaemia, skeletal muscle protein synthesis, and intramyocellular anabolic signalling in older adults are worthy of investigation. FPH may represent beneficial and sustainable alternative sources of high-quality protein to support skeletal muscle health and anabolism in ageing, without compromising appetite and subsequent energy intake.
- |||||||||| Journal: Frailty and sarcopenia in combination are more predictive of mortality than either condition alone. (Pubmed Central) - Mar 18, 2021
Therefore, the expression or activity of Grx1 may be a pharmacological approach to ameliorate muscle atrophy diseases, such as sarcopenia. Individuals identified as frail would benefit from screening and assessment for sarcopenia, and vice versa for those identified as sarcopenic, as the mortality risk for individuals with these conditions in combination is nearly double that of each separately.
|